MedTrace Logo

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04781374 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-07-11

No results posted yet for this study

Summary

This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment.

\- The names of the study drug involved in this study is neratinib.

Conditions

  • Metastatic Prostate Adenocarcinoma
  • Castration-resistant Prostate Cancer
  • Prostate Cancer
  • Prostate Cancer Metastatic

Interventions

DRUG

Neratinib

Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,

Sponsors & Collaborators

Principal Investigators

  • David Einstein, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-21
Primary Completion
2021-09-24
Completion
2021-09-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04781374 on ClinicalTrials.gov